Celgene Moves Into Solid Tumors With $2.9 Billion Abraxis Acquisition
Celgene Corp. is acquiring Abraxane developer Abraxis BioScience and planning an aggressive development and marketing push for the novel nanoparticle formulation of paclitaxel, with the aim of driving the drug’s sales to $1 billion by 2015.
You may also be interested in...
The US agency has released a document explaining what COVID-19 testing supplies may be substituted.
Marketing consultant Buzzback surveyed 800 consumers in March, prior to novel coronavirus shutdowns in the two countries, to identify ingredients that offer opportunities for brands in health care, wellness and skin care.
AstraZeneca and Accent Therapeutics will jointly discover, develop and commercialize novel therapeutics targeting RNA-modifying proteins for the treatment of cancer.